Here below are the publications (1) participated by Ilaria Colombo along with Marta Nerone (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).
Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch
Ilaria Colombois currently collaborating with
Istituto Oncologico Svizzera Italiana (IOSI) (Rif. IOSI)
Via Gallino 12 (ex Via Ospedale)
6500 Bellinzona
Ilaria Colombo
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Maintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo controlled multi-center phase III Trial (ENGOT-ov54/Swiss GO-2/MATAO) including LOGOS (Low Grade Ovarian cancer Sub-study) Clinical Study (Rif. 19000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Maintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo controlled multi-center phase III Trial (ENGOT-ov54/Swiss GO-2/MATAO) including LOGOS (Low Grade Ovarian cancer Sub-study) Clinical Study (Rif. 19000 202407)
Ilaria Colombo
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (ENGOT-en23/GOG3095) (Rif. 20000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (ENGOT-en23/GOG3095) (Rif. 20000 202407)
Ilaria Colombo
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (Rif. 16000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (Rif. 16000 202407)
Ilaria Colombo
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid Tumors (Rif. 10000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid Tumors (Rif. 10000 202407)
Ilaria Colombo
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Two-part, first-in-human study on ODM-212 in subjects with selected advanced solid tumours (Rif. 09000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Two-part, first-in-human study on ODM-212 in subjects with selected advanced solid tumours (Rif. 09000 202407)
Ilaria Colombo
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 1/1b Open-label, Multicenter Clinical Study of MK 0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors (Rif. 05000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 1/1b Open-label, Multicenter Clinical Study of MK 0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors (Rif. 05000 202407)
Ilaria Colombo
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (Rif. 04000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (Rif. 04000 202407)